 3. Conditions in the previous dupilumab study consistent with protocol-defined criteria for permanent study drug discontinuation, if deemed related to dupilumab or led to investigator - or sponsor-initiated withdrawal of patient from the study eg, non-compliance, inability to complete study assessments, etc.. 